Ivan Bunganič
Publications by Year
Research Areas
Inflammatory Bowel Disease, Gastrointestinal disorders and treatments, Microscopic Colitis, Diverticular Disease and Complications, Tuberculosis Research and Epidemiology
Most-Cited Works
- → Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn’s Disease(2022)91 cited
- → Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease(2010)90 cited
- → 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial(2010)61 cited
- → ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension(2022)59 cited
- → Long‐term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)—results from the European phase 3 open‐label safety trial(2018)51 cited
- → Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial(2014)48 cited
- → Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence(2017)47 cited
- → 808 Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial of Mesalamine for the Prevention of Recurrence of Diverticulitis(2013)16 cited
- → 83 Efficacy and Tolerability of a Once Daily Treatment with Budesonide Capsules Versus Mesalamine Granules for the Treatment of Active Ulcerative Colitis: A Randomized, Double-Blind, Double-Dummy, Multicenter Study(2009)8 cited
- → Rifamycin vs placebo for the treatment of acute uncomplicated diverticulitis: A randomised, double‐blind study(2020)6 cited